Indication · To treat pulmonary arterial hypertension

To treat pulmonary arterial hypertension FDA approvals, PDUFA dates and pipeline.

Updated Snapshot 20261116T112050ZBuilt

We track 1 To treat pulmonary arterial hypertension drug. 1 FDA approval recorded, most recently Winrevair (sotatercept-csrk) on March 26, 2024.

Drugs

DrugSponsorModalityDesignations
Winrevair (sotatercept-csrk)MRKbiologicPriority Review

Upcoming catalysts

No events in this view.

Past catalysts and decisions

DateDrugCompanyEventIndicationStatusSource
March 26, 2024Winrevair (sotatercept-csrk)MRKFDA approvalTo treat pulmonary arterial hypertensionApprovedFDA Novel Drug Approvals

All indications · Approval rates by indication

Not submitted to search engines: Needs 2 drugs and 3 sourced events; has 1 and 1.

Questions

What To treat pulmonary arterial hypertension drugs have upcoming PDUFA dates?

None disclosed.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.